secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2026-02-20T23:59:59+00:00
Accession:  0001171843-26-000979
Event type: litigation
Sentiment:  positive
Materiality: 0.82
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus wins partial summary judgment in Moderna patent case; enablement goes to trial
--------------------------------------------------------------------------------

- Court bars Moderna's obviousness defense: IPR estoppel applies to '435 Patent, issue preclusion bars routine-optimization and phospholipid-range arguments.
- Arbutus's motion to exclude Moderna's obviousness expert Dr. Anderson granted.
- Moderna's enablement defense survives: Dr. Prud'homme's testimony creates genuine factual dispute; trial needed on whether claims require undue experimentation.
- Moderna's derivation defense dismissed for lack of evidence.
- Court upholds that prior IPR final written decisions trigger statutory estoppel even without appeal; Moderna cannot relitigate previously rejected arguments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326000979/0001171843-26-000979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326000979/f8k_021926.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer